Vanguard Group Inc Cytosorbents Corp Call Options Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CTSO
# of Institutions
52Shares Held
16.7MCall Options Held
28.9KPut Options Held
0-
Avenir Corp Washington, DC5.06MShares$4.7 Million0.7% of portfolio
-
Skylands Capital, LLC2.62MShares$2.43 Million0.55% of portfolio
-
Neuberger Berman Group LLC New York, NY1.59MShares$1.48 Million0.0% of portfolio
-
Cm Management, LLC1.25MShares$1.16 Million1.64% of portfolio
-
Sargent Investment Group, LLC746KShares$693,9660.14% of portfolio
About Cytosorbents Corp
- Ticker CTSO
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 43,577,400
- Market Cap $40.5M
- Description
- Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunct...